Zomanex is a specialty pharmaceutical company dedicated to the development of pharmaceutical products based on the patent pending OraZom drug delivery platform. OraZom allows hydrophobic compounds to be efficiently absorbed in the small intestine. Their initial research effort is focused on the use of the OraZom technology for the conversion of intravenous or injectable xenobiotics into orally deliverable products. The initial market will be the conversion to oral dosing of proven oncology compounds currently available only in an intravenous form. OraZom 3907, the lead product opportunity, is an application of OraZom to paclitaxel, an effective and off-patent chemotherapeutic agent.